Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia

[1]  A. Williams,et al.  PRO153 PSYCHOMETRIC VALIDATION OF THE PROMIS PHYSICAL FUNCTION MOBILITY, PAIN INTERFERENCE AND FATIGUE IN A COHORT OF PAEDIATRIC X-LINKED HYPOPHOSPHATEMIA (XLH) PATIENTS , 2019, Value in Health.

[2]  F. Glorieux,et al.  Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial , 2019, The Lancet.

[3]  J. S. San Martin,et al.  The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey , 2019, Journal of the Endocrine Society.

[4]  J. S. San Martin,et al.  Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score. , 2019, Bone.

[5]  J. S. San Martin,et al.  Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. , 2019, The lancet. Diabetes & endocrinology.

[6]  K. Lyseng-Williamson.  Burosumab in X-linked hypophosphatemia: a profile of its use in the USA , 2018, Drugs & Therapy Perspectives.

[7]  M. Collins.  Burosumab: At Long Last, an Effective Treatment for FGF23‐Associated Hypophosphatemia , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  J. S. San Martin,et al.  Burosumab Therapy in Children with X‐Linked Hypophosphatemia , 2018, The New England journal of medicine.

[9]  Ching-Huang Lai,et al.  Exploring the Link between Serum Phosphate Levels and Low Muscle Strength, Dynapenia, and Sarcopenia , 2018, Scientific Reports.

[10]  W. Polonsky,et al.  Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes , 2017, Diabetes Care.

[11]  S. Kashikar-Zuck,et al.  Development and validation of the self-reported PROMIS pediatric pain behavior item bank and short form scale , 2017, Pain.

[12]  K. Bevans,et al.  Patient‐Reported Outcomes Measurement Information System Tools for Collecting Patient‐Reported Outcomes in Children With Juvenile Arthritis , 2017, Arthritis care & research.

[13]  A. Carle,et al.  Validation of Patient‐Reported Outcomes Measurement Information System Short Forms for Use in Childhood‐Onset Systemic Lupus Erythematosus , 2017, Arthritis care & research.

[14]  Christopher F. Martin,et al.  Patient-Reported Outcomes Measurement Information System in Children with Crohn's Disease. , 2016, The Journal of pediatrics.

[15]  K. Petersen,et al.  Hypophosphatemia promotes lower rates of muscle ATP synthesis , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  B. Reeve,et al.  Initial Evaluation of the Pediatric PROMIS® Health Domains in Children and Adolescents With Sickle Cell Disease , 2016, Pediatric blood & cancer.

[17]  J. Tobert,et al.  Statin tolerability: In defence of placebo-controlled trials , 2015, European journal of preventive cardiology.

[18]  F. Glorieux,et al.  Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. , 2015, The Journal of clinical endocrinology and metabolism.

[19]  P. Hinds,et al.  PROMIS® pediatric self-report scales distinguish subgroups of children within and across six common pediatric chronic health conditions , 2015, Quality of Life Research.

[20]  H. Khoury,et al.  The role of observational studies in optimizing the clinical management of chronic myeloid leukemia , 2015, Therapeutic advances in hematology.

[21]  M. Peacock,et al.  Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. , 2014, The Journal of clinical investigation.

[22]  P. Wicart,et al.  Therapeutic management of hypophosphatemic rickets from infancy to adulthood , 2014, Endocrine connections.

[23]  S. Acaster,et al.  Methods for interpreting change over time in patient-reported outcome measures , 2013, Quality of Life Research.

[24]  C. Forrest,et al.  Advances in Patient-Reported Outcomes: The NIH PROMIS® Measures , 2013, EGEMS.

[25]  D. Allen,et al.  The multiple roles of phosphate in muscle fatigue , 2012, Front. Physio..

[26]  F. Rauch,et al.  Abnormalities in muscle density and muscle function in hypophosphatemic rickets. , 2012, The Journal of clinical endocrinology and metabolism.

[27]  A. Kroon,et al.  Participation in a Clinical Trial Enhances Adherence and Persistence to Treatment: A Retrospective Cohort Study , 2011, Hypertension.

[28]  I. Holm,et al.  A clinician's guide to X‐linked hypophosphatemia , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  J. Varni,et al.  Sampling plan and patient characteristics of the PROMIS pediatrics large-scale survey , 2010, Quality of Life Research.

[30]  C. L. Hicks,et al.  The Faces Pain Scale – Revised: toward a common metric in pediatric pain measurement , 2001, Pain.

[31]  Byron C. Jaeger,et al.  Assessing responsiveness over time of the PROMIS® pediatric symptom and function measures in cancer, nephrotic syndrome, and sickle cell disease , 2017, Quality of Life Research.

[32]  Brooke E. Magnus,et al.  Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method , 2015, Quality of Life Research.

[33]  J. Wit,et al.  The proxy problem: child report versus parent report in health-related quality of life research , 2004, Quality of Life Research.

[34]  Byron C. Jaeger,et al.  Responsiveness of PROMIS (R) Pediatric Measures to Hospitalizations for Sickle Pain and Subsequent Recovery , 2022 .